Cargando…

HPV vaccine recommendations by age: A survey of providers in federally qualified health centers

Clinician recommendation remains a critical factor in improving HPV vaccine uptake. Clinicians practicing in federally qualified health centers were surveyed between October 2021 and July 2022. Clinicians were asked how they recommended HPV vaccination for patients aged 9–10, 11–12, 13–18, 19–26, an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lake, Paige, Fuzzell, Lindsay, Brownstein, Naomi C., Fontenot, Holly B., Michel, Alexandra, McIntyre, McKenzie, Whitmer, Ashley, Rossi, Sarah L., Perkins, Rebecca B., Vadaparampil, Susan T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	HPV
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054304/ https://www.ncbi.nlm.nih.gov/pubmed/36882951 http://dx.doi.org/10.1080/21645515.2023.2181610

Ejemplares similares

Examining the perceived impact of the COVID-19 pandemic on cervical cancer screening practices among clinicians practicing in Federally Qualified Health Centers: A mixed methods study
por: Fuzzell, Lindsay, et al.
Publicado: (2023)

Examining the association of clinician characteristics with perceived changes in cervical cancer screening and colposcopy practice during the COVID-19 pandemic: a mixed methods assessment
por: Fuzzell, Lindsay, et al.
Publicado: (2023)

Optimizing timing of adolescent vaccines: Impact of initiating HPV vaccination before Tdap or meningococcal vaccination on timely completion of the HPV vaccine series
por: Kajtezovic, Sidika, et al.
Publicado: (2023)

Parents’ stigmatizing beliefs about the HPV vaccine and their association with information seeking behavior and vaccination communication behaviors
por: McKenzie, Ashley Hedrick, et al.
Publicado: (2023)

Framing of national HPV vaccine recommendations and willingness to recommend at ages 9-10
por: Kahn, Benjamin Z., et al.
Publicado: (2023)

Does HPV vaccination initiation at age 9, improve HPV initiation and vaccine series completion rates by age 13?
por: O’Leary, Sonja C., et al.
Publicado: (2023)

How to make effective HPV vaccine recommendations starting at age 9
por: Brewer, Noel T., et al.
Publicado: (2023)

A questionnaire survey on the prevention of HPV infection among females and males who came of age in Japan under various scenarios of HPV vaccine recommendation
por: Ishimoto, Tatsuki, et al.
Publicado: (2023)

Recommending HPV vaccination at age 9 to reduce health disparities: Communication challenges and opportunities
por: Coyne-Beasley, Tamera, et al.
Publicado: (2023)

Incorporating Stakeholder Feedback in Guidelines Development for the Management of Abnormal Cervical Cancer Screening Tests
por: Perkins, Rebecca B., et al.
Publicado: (2020)

HPV vaccine information, knowledge, attitude, and recommendation intention among male college students in China
por: Wu, Huamei, et al.
Publicado: (2023)

The influence of political ideology on awareness of HPV and HPV vaccine among adults in the United States
por: Chido-Amajuoyi, Onyema Greg, et al.
Publicado: (2023)

Social and psychological impact of HPV testing in cervical screening: a qualitative study
por: McCaffery, K, et al.
Publicado: (2006)

Individual, systemic and state factors associated with provider recommendation of HPV vaccination: Findings from NIS-Teen, 2020
por: Osaghae, Ikponmwosa, et al.
Publicado: (2023)

Human papillomavirus (HPV) vaccines in adults: Learnings from long-term follow-up of quadrivalent HPV vaccine clinical trials
por: Goldstone, Stephen E.
Publicado: (2023)

HPV vaccine knowledge, attitudes, and practices among New York State medical providers, dentists, and pharmacists
por: Fernandes, Annlynn, et al.
Publicado: (2023)

Prevalence and human papillomavirus (HPV) genotype distribution in Suzhou, China
por: Wang, Tianyu, et al.
Publicado: (2023)

Multilevel perspectives on school-based opportunities to improve HPV vaccination among medically underserved adolescents: Beyond school entry mandates
por: Shin, Michelle B., et al.
Publicado: (2023)

Engaging health plans to prioritize HPV vaccination and initiate at age 9
por: Foley, Shaylen, et al.
Publicado: (2023)

Safety and immunogenicity of a bivalent HPV16/18 vaccine in Chinese females
por: Shi, Li-Wei, et al.
Publicado: (2023)

Descriptive epidemiology of age at HPV vaccination: Analysis using the 2020 NIS-Teen
por: Bednarczyk, Robert A., et al.
Publicado: (2023)

Implementing interventions to start HPV vaccination at age 9: Using the evidence we have
por: Brandt, Heather M., et al.
Publicado: (2023)

Pediatric hematology and oncology physician and nurse practitioner views of the HPV vaccine and barriers to administration
por: Miller, Meagan E., et al.
Publicado: (2023)

Post-marketing surveillance study of the safety of the HPV-16/18 vaccine in Korea (2017–2021)
por: Eun, Byung-Wook, et al.
Publicado: (2023)

Feminized vaccine? Parents’ attitudes toward HPV vaccination of adolescents in Poland: A representative study
por: Sobierajski, Tomasz, et al.
Publicado: (2023)

HPV prevalence and genotype distribution among women in eastern China during the Covid-19 pandemic
por: Ma, Yongmei, et al.
Publicado: (2023)

Multiple infections containing the top five prevalent HPV genotypes and their impact on cervical lesions in Changzhou, China
por: Gong, Ping, et al.
Publicado: (2023)

Willingness to get HPV vaccination among female university students in Kuwait and its relation to vaccine conspiracy beliefs
por: Alsanafi, Mariam, et al.
Publicado: (2023)

Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong
por: Cheung, Tak Hong, et al.
Publicado: (2023)

Association of provider HPV vaccination training with provider assessment of HPV vaccination status and recommendation of HPV vaccination
por: Osaghae, Ikponmwosa, et al.
Publicado: (2022)

AN UPWARD TREND IN DNA P16INK4A METHYLATION PATTERN AND HIGH RISK HPV INFECTION ACCORDING TO THE SEVERITY OF THE CERVICAL LESION
por: Carestiato, Fernanda Nahoum, et al.
Publicado: (2013)

HPV vaccine initiation at 9 or 10 years of age and better series completion by age 13 among privately and publicly insured children in the US
por: Saxena, Kunal, et al.
Publicado: (2023)

Human papillomavirus vaccination at the first opportunity: An overview
por: Bednarczyk, Robert A., et al.
Publicado: (2023)

The association of initiating HPV vaccination at ages 9–10 years and up-to-date status among adolescents ages 13–17 years, 2016-2020
por: Minihan, Adair K., et al.
Publicado: (2023)

Perceptions and acceptability of HPV vaccination among parents of female adolescents 9–14 in China: A cross-sectional survey based on the theory of planned behavior
por: Yi, Youqin, et al.
Publicado: (2023)

Multi-level quality improvement strategies to optimize HPV vaccination starting at the 9-year well child visit: Success stories from two private pediatric clinics
por: Zorn, Sherri, et al.
Publicado: (2023)

An investigation on cervical cancer and human papillomavirus vaccine knowledge, and analysis of influencing factors for choosing domestic or imported 2vHPV vaccine among females in Shenzhen, China
por: Chen, Linxiang, et al.
Publicado: (2023)

Parents’ willingness to vaccinate their daughters with human papillomavirus vaccine and associated factors in Debretabor town, Northwest Ethiopia: A community-based cross-sectional study
por: Aragaw, Getie Mihret, et al.
Publicado: (2023)

Key ethical considerations to guide the adjudication of a single-dose HPV vaccine schedule
por: Shadab, Ruha, et al.
Publicado: (2021)

Changing trends in HPV vaccination in Japan
por: Ujiie, Mugen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e45cdipegs7dteo9klfkkgpmqg